Public panic during the Irkutsk incident was exacerbated by the circulation of sensationalist literature that often conflates legitimate scientific research with offensive biological warfare. The death of a seasoned researcher at the Irkutsk Anti-Plague Research Institute in October 2026 has become
The sheer complexity of microbial ecosystems has long outpaced the technological ability to map them with granular precision at the species level. While highly effective in common biomes, the tool faces limitations in less-studied dark biomes due to the incompleteness of reference databases. This
The Light Gradient Boosting Machine emerged as the most effective tool for calculating the probability of plaque rupture based on systemic biological indicators. This innovative approach addresses the critical challenge of identifying vulnerable carotid plaques before they lead to catastrophic
Advanced deep learning has reached a pivotal moment in medical imaging with the introduction of a dual-branch architecture that identifies brain tumors with exceptional precision. As of 2026, the medical community continues to face an overwhelming surge in diagnostic imaging data, placing an
Anthropic’s IPO filing puts a sharper question before biopharma: how far should an AI supplier move into the science its customers depend on? In its SEC prospectus, substantial spending by major drugmakers sits alongside plans for a molecular biology lab and an internal discovery program. Investors
The development of experimental treatments for muscular dystrophy is moving toward human trials in 2028 following encouraging results in preclinical mouse models. This milestone represents a significant leap in the application of Anthropic's Claude AI within the pharmaceutical sector, specifically
